Nuvalent (NASDAQ:NUVL) Sees Strong Trading Volume – Here’s Why

Nuvalent, Inc. (NASDAQ:NUVL) shares saw strong trading volume on Thursday . 1,265,389 shares were traded during mid-day trading, a decline of 2% from the previous session’s volume of 1,285,246 shares.The stock last traded at $123.4750 and had previously closed at $123.36.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. UBS Group cut shares of Nuvalent from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $138.00 to $124.00 in a research report on Wednesday, June 10th. TD Cowen lowered shares of Nuvalent from a “buy” rating to a “hold” rating and set a $124.00 price target on the stock. in a report on Tuesday, June 9th. Robert W. Baird set a $122.85 price target on shares of Nuvalent in a report on Tuesday, June 9th. Piper Sandler lowered shares of Nuvalent from an “overweight” rating to a “neutral” rating and set a $124.00 price target on the stock. in a report on Tuesday, June 9th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Nuvalent in a report on Wednesday, June 10th. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nuvalent presently has a consensus rating of “Hold” and an average target price of $131.15.

Nuvalent Stock Up 0.0%

The company’s fifty day moving average is $105.32 and its 200 day moving average is $103.71. The stock has a market cap of $9.75 billion, a PE ratio of -20.36 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the previous year, the firm posted ($1.18) EPS. Equities analysts expect that Nuvalent, Inc. will post -5.74 EPS for the current year.

Insider Activity

In other news, insider Deborah Ann Miller sold 5,500 shares of Nuvalent stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total transaction of $593,120.00. Following the sale, the insider owned 59,634 shares in the company, valued at $6,430,930.56. This trade represents a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Henry E. Pelish sold 3,093 shares of Nuvalent stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total transaction of $323,156.64. Following the sale, the insider owned 65,604 shares in the company, valued at $6,854,305.92. This represents a 4.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 126,953 shares of company stock worth $12,612,264. Company insiders own 5.02% of the company’s stock.

Institutional Trading of Nuvalent

Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC raised its stake in shares of Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after purchasing an additional 108 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Nuvalent by 141.3% during the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after purchasing an additional 195 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in shares of Nuvalent during the third quarter valued at approximately $38,000. NBC Securities Inc. purchased a new stake in shares of Nuvalent during the fourth quarter valued at approximately $125,000. Finally, KBC Group NV raised its stake in shares of Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after purchasing an additional 297 shares during the period. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.